Claims for Patent: 6,224,863

Summary for Patent: 6,224,863

Title:	Antibiotic composition from alcaligenes species and method for making and using the same
Abstract:	A method and composition for treating a bacterial infection in humans and animals is disclosed. The composition contains an anti-bacterial agent that inhibits or kills a variety of Gram-negative and Gram-positive pathogenic bacteria, including several previously shown to be drug-resistant. In particular, the anti-bacterial agent comprises an antibiotic produced by members of the Alcaligenes genus. For instance, in one embodiment, the antibiotic is produced by the M3A strain of Alcaligenes faecalis. The antibiotic of the present invention can be administered parenterally or via a mucosal route.
Inventor(s):	Bacic; Melissa K. (Columbia, SC), Yoch; Duane C. (Columbia, SC)
Assignee:	University of South Carolina (Columbia, SC)
Application Number:	09/201,754
Patent Claims:	1. A method for treating a bacterial infection in a patient, comprising the steps of: administering to said patient a composition containing an anti-bacterial agent, said anti-bacterial agent comprising an antibiotic produced by culturing the M3A strain of Alcaligenes faecalis under aerobic conditions and at a temperature within a range of from 17.degree. C. to 43.degree. C. on a culture medium containing a citrate or succinate carbon source until sufficient antibotic activity is produced in said medium, wherein said antibiotic is administered in a therapeutically active dosage for a time effective to inhibit the growth of said bacterial infection in said patient. 2. A method according to claim 1, wherein said composition is administered via mucosal administration. 3. A method according to claim 1, wherein said composition is administered via parenteral administration. 4. A method according to claim 1, wherein said composition further comprises a pharmaceutically acceptable carrier. 5. A method according to claim 4, wherein said pharmaceutically acceptable carrier is chosen from the group consisting of physiological saline, dextrose, sterile water, and mixtures thereof. 6. A method according to claim 1, wherein said antibiotic is administered in a therapeutically active dosage, for a time effective to kill the bacteria in said bacterial infection. 7. A method according to claim 1, wherein said therapeutically active dosage is in the range of about 0.2 .mu.g per kilogram of body weight per minute to about 200 g per kilogram of body weight per minute. 8. An anti-microbial composition for treating a bacterial infection in a human or animal patient, said composition comprising an antibiotic produced by the M3A strain of Alcaligenes faecalis bacterial and a pharmaceutically acceptable carrier, wherein said M3A strain of Alcaligenes faecalis bacteria is cultured under aerobic conditions and at a temperature within a range of from 17.degree. C. to 43.degree. C. on a culture medium containing a citrate or succinate carbon source until sufficient antibiotic activity is produced in said medium. 9. An antimicrobial composition as in claim 8, wherein said pharmaceutically acceptable carrier is chosen from the group consisting of physiological saline, dextrose, sterile water, and mixtures thereof. 10. An antimicrobial composition as in claim 8, wherein said composition is in the form of a sterile injectable formulation. 11. An antimicrobial composition as in claim 8, wherein said composition is formulated as a sterile solid, and said sterile solid is chosen from the group consisting of tablets, capsules, suppositories, and liquids. 12. An antimicrobial composition as in claim 8, wherein said composition is formulated to deliver a therapeutically active dosage in the range of about 0.2 .mu.g per kilogram of body weight per minute to about 200 g per kilogram of body weight per minute.

Details for Patent 6,224,863

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2018-10-30